AbbVie eczema candidate has analysts whittling down super-rich forecasts for Sanofi and Regeneron's Dupixent
admin 8th September 2017 Uncategorised 0Regeneron and Sanofi’s new injected immunology drug Dupixent has taken off like a rocket, leading to some lofty projections for its peak upside. Like $10 billion-plus. But with some easier-to-take oral competitors percolating in pipelines, some analysts believe it is time to take at least a little of the air out of those forecasts.
More: AbbVie eczema candidate has analysts whittling down super-rich forecasts for Sanofi and Regeneron's Dupixent
Source: fierce